William R. Ringo - Mar 8, 2022 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role: Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: SNSE
Transactions as of: Mar 8, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/9/2022, 05:24 PM
Previous filing: May 24, 2021
Next filing: May 27, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNSE	Common Stock	Award	$0	+8.93K		$0.00	8.93K	Mar 8, 2022	Direct	F1
transaction	SNSE	Common Stock	Award	$0	+10K	+111.94%	$0.00	18.9K	Mar 8, 2022	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNSE	Stock Option (Right to Buy)	Award	$0	+29.1K		$0.00	29.1K	Mar 8, 2022	Common Stock	29.1K	$3.08	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in three equal annual installments on each of March 8, 2023, March 8, 2024, and March 8, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2	These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, on March 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F3	Includes 8,933 shares acquired by the Reporting Person as of March 8, 2022 as an RSU award.
F4	The shares subject to the option vest monthly over thirty-six (36) months from the vesting commencement date, March 8, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.